We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
-19.33%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$335M
AUM Growth
-$24.9M
Cap. Flow
+$60.4M
Cap. Flow %
18.05%
Top 10 Hldgs %
58.78%
Holding
55
New
11
Increased
22
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$17.8M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$11.9M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$11.5M
4
ACCD
Accolade Inc
ACCD
+$11.3M
5
ADCT icon
ADC Therapeutics
ADCT
+$10M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$12.3M
2
GH icon
Guardant Health
GH
+$9.7M
3
KURA icon
Kura Oncology
KURA
+$6.79M
4
KIDS icon
OrthoPediatrics
KIDS
+$6.68M
5
PFE icon
Pfizer
PFE
+$5.97M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Industrials 4.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GH icon
51
Guardant Health
GH
$19.5B
– –
-470,000
Closed -$9.7M
MRVI icon
52
Maravai LifeSciences
MRVI
$997M
– –
-599,460
Closed -$5.2M
NUVB icon
53
Nuvation Bio
NUVB
$2.24B
– –
-250,000
Closed -$910K
PCRX icon
54
Pacira BioSciences
PCRX
$1.02B
– –
-94,362
Closed -$2.76M
PFE icon
55
Pfizer
PFE
$140B
– –
-215,000
Closed -$5.97M
1 2
3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q2 2024 Portfolio in Review

As of Q2 2024, Prosight Management held 55 positions worth $335M, down 6.9% from $359M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Prosight Management deployed $60.4M of net new capital in Q2 2024, opening 11 new positions and adding to 22 existing holdings. Its largest new stake was Syndax Pharmaceuticals: 551,544 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Medtronic, an estimated $12.3M trimmed.

  • Prosight Management's largest Q2 2024 buy was Syndax Pharmaceuticals: 551,544 shares worth $11.3M.
  • Prosight Management added most to Zimmer Biomet in Q2 2024, an estimated $17.8M increase.
  • Prosight Management's biggest Q2 2024 reduction was Medtronic, cutting an estimated $12.3M.
  • Prosight Management fully exited Guardant Health in Q2 2024, selling an estimated $9.7M.
  • Prosight Management's ten largest holdings make up 59% of its $335M portfolio in Q2 2024.
  • Prosight Management opened 11 new positions and closed 9 in Q2 2024.
  • Prosight Management's portfolio value fell 6.9% quarter-over-quarter to $335M.

Based on Prosight Management's 13F filing for Q2 2024, filed 14 Aug 2024.